Zhitong Finance App News, Shanghai Pharmaceutical (02607) announced that recently, Shanghai Shangyao Ruier Pharmaceutical Co., Ltd., a subsidiary of the company, received the approval and issuance of a “Pharmaceutical Clinical Trial Approval Notice” for triprostenil diethanolamine inhalation powder from the State Drug Administration.

Triprostenil diethanolamine inhalation powder is a Class 2.2 improved innovative drug. The active ingredient is triprostinil diethanolamine, which is an artificially synthesized prostacyclin derivative. It is intended to treat pulmonary hypertension (PAH, WHO Group 1) to reduce symptoms associated with exercise. Its mechanism of action mainly works by directly dilating pulmonary and systemic arterial vascular beds and inhibiting platelet aggregation. As of the disclosure date of this announcement, the project has invested a total of approximately RMB 21.41 million in R&D expenses.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.